21 May 2013
Keywords: positive, ph, iib, data, ipsat, p1a, helsinki
Article | 05 November 2007
Helsinki, Finland-based Ipsat Therapies says that the Ipsat P1A Phase IIb study met both primary endpoints. The agent is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 November 2007
20 May 2013
© 2013 thepharmaletter.com